|
|
 Blood Information - September 7, 2008
| The Food and Drug Administration is considering the use of leeches and maggots in more medical procedures. Lisa Darmo, of Carolina Biological Supply in Burlington, says special leeches for medical use only are imported from England and shipped to hospitals across the country | | After conducting tests on several prominent Californians, a health advocacy group finds traces of high exposure to dangerous chemicals. Commonwealth's study finds their subjects, including actor Peter Coyote, newspaper columnist Steve Lopez, and nine other influential state residents, have dangerously high amounts of toxic chemicals in their systems | | An oyster fisherman is awarded $14 million in damages after claiming chemicals from a DuPont factory caused him to develop a rare form of blood cancer. The verdict is a first in some 2,000 lawsuits against the plant. According to a jury, DuPont DeLisle is responsible for Glen Strong's multiple myeloma. Strong's wife was given $1.5 million for loss of "love and companionship." The jury will meet again Monday to decide on punitive damages. DuPont officials plan to appeal. Says DuPont spokeswoman Mary Kate Campbell, "There is no connection between our operations and any health effects alleged by the plaintiffs." Strong and 1,995 other plaintiffs have filed lawsuits claiming releases of dioxins from the plant are causing a variety of health problems among the surrounding communities | | A treatment used for acute heavy-metal poisoning is used on an autistic boy, causing him to go into cardiac arrest on Tuesday. Abubakar Tariq Nadama, 5, died in a doctor's office after receiving the treatment that some people believe may cure the neurological and developmental disorder, officials say | | Third Wave Technologies Inc. wins U.S. approval Monday to market a genetic blood test that could help make certain medicines more personalized, allowing doctors to adjust drug dosages accordingly, and minimizes side effects. The Food and Drug Administration says the Invader UGT1A1 Molecular Assay has so far only been shown to work with Pfizer Inc's colon cancer drug Camptosar, but future data could link it to other drugs | |
|
|